Evidence map›Paper›PMID 28195652›Full record

ArticleBritish journal of pharmacology2017

Identification of the anti-mycobacterial functional properties of piperidinol derivatives.

Collette S Guy, Esther Tichauer, Gemma L Kay, Daniel J Phillips, Trisha L Bailey, James Harrison, Christopher M Furze, Andrew D Millard, Matthew I Gibson, Mark J Pallen and 1 more

Abstract read
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Collette S GuySchool of Life Sciences, University of Warwick, Coventry, UK.
Esther TichauerSchool of Life Sciences, University of Warwick, Coventry, UK.
Gemma L KayMedical School, University of Warwick, Coventry, UK.
Daniel J PhillipsDepartment of Chemistry, University of Warwick, Coventry, UK.
Trisha L BaileyDepartment of Chemistry, University of Warwick, Coventry, UK.
James HarrisonSchool of Life Sciences, University of Warwick, Coventry, UK.
Christopher M FurzeSchool of Life Sciences, University of Warwick, Coventry, UK.
Andrew D MillardMedical School, University of Warwick, Coventry, UK.
Matthew I GibsonDepartment of Chemistry, University of Warwick, Coventry, UK.ORCID http://orcid.org/0000-0002-8297-1278
Mark J PallenMedical School, University of Warwick, Coventry, UK.
Elizabeth FullamSchool of Life Sciences, University of Warwick, Coventry, UK.ORCID http://orcid.org/0000-0001-6245-1614

Funding

European Research Council 638661Medical Research Council MR/L015080/1Medical Research Council MR/N006917/1Wellcome Trust
6 · The paper itself

Abstract

background and purposeTuberculosis (TB) remains a major global health threat and is now the leading cause of death from a single infectious agent worldwide. The current TB drug regimen is inadequate, and new anti-tubercular agents are urgently required to be able to successfully combat the increasing prevalence of drug-resistant TB. The purpose of this study was to investigate a piperidinol compound derivative that is highly active against the Mycobacterium tuberculosis bacillus. EXPERIMENTAL APPROACH: The antibacterial properties of the piperidinol compound and its corresponding bis-Mannich base analogue were evaluated against M. smegmatis and Gram-negative organisms. Cytotoxicity studies were undertaken in order to determine the selectivity index for these compounds. Spontaneous resistant mutants of M. smegmatis were generated against the piperidinol and corresponding bis-Mannich base lead derivatives and whole genome sequencing employed to determine the genetic modifications that lead to selection pressure in the presence of these compounds. KEY

resultsThe piperidinol and the bis-Mannich base analogue were found to be selective for mycobacteria and rapidly kill this organism with a cytotoxicity selectivity index for mycobacteria of >30-fold. Whole genome sequencing of M. smegmatis strains resistant to the lead compounds led to the identification of a number of single nucleotide polymorphisms indicating multiple targets. CONCLUSION AND IMPLICATIONS: Our results indicate that the piperidinol moiety represents an attractive compound class in the pursuit of novel anti-tubercular agents. LINKED ARTICLES: This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro-organisms. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc.

Indexed as

Anti-Bacterial AgentsCell SurvivalDose-Response Relationship, DrugEscherichia coliHumansMicrobial Sensitivity TestsMolecular StructureMycobacterium smegmatisPiperidinesPolymorphism, Single NucleotidePseudomonas putidaStructure-Activity RelationshipTumor Cells, CulturedAnti-Bacterial AgentsPiperidines

Identifiers

PMID28195652
PMCPMC5481654

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.